In several types of human cancer, the gene expression of Reprimo, a highly glycosylated protein, is frequently silenced via methylation of its promoter. The aim of this study was to characterize the epigenetic inactivation of Reprimo and its biological function and clinical relevance in gastric cancer (GC). The correlation between Reprimo methylation and clinical relevance was assessed in 83 primary human GC tissues. The effects of Reprimo expression were also examined using in vitro and in vivo assays. Reprimo methylation was cancerspecific and frequently observed. In two GC cell lines without Reprimo methylation, we observed faint or weak Reprimo expression under normal conditions and high expression under DNA-damaging conditions. In four GC cell lines with Reprimo methylation, however, Reprimo expression remained faint even under DNA damaging conditions, with expression being restored in combination with agents that induce demethylation. Enforced
Introduction
Transiently enforced Reprimo expression induces G2 arrest of the cell cycle by inhibiting Cdc2 activity and nuclear translocation of the Cdc2-cyclin B1 complex in various cell lines such as DLD1, HeLa and MCF7 cells (9) , whereas loss of Reprimo expression is associated with an increase in uterine sarcoma incidence in mutant p53 transgenic mice treated with the carcinogen 1,2-dimethylhydrazine (10) . These findings suggest that both the expression and function of Reprimo as a tumor-suppressor gene are regulated in a p53-dependent manner. In contrast, Reprimo promoter methylation has been reported to be involved in an alternative mechanism that regulates Reprimo expression in various types of tumors (11) (12) (13) . Further, the regulation of Reprimo expression is independent of p53 status in neuronal cells treated with copper, with neuronal damage being associated with Wilson's disease (14) . In GC, Reprimo promoter methylation is a frequent event as we, and others, have previously reported (11, 13, 15) . The relationship between Reprimo and GC, however, has never been examined from a mechanistic and functional point of view
In the present study, we examined the clinical significance of the Reprimo gene, especially for its promoter methylation in primary GC and assessed the functional change associated with its abnormality. NUGC4) were purchased from RIKEN BioResource Center (Ibaraki, Japan) in December 2006. All cell lines were grown in RPMI 1640 medium (GIBCO, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS). We confirmed the authenticity of the cell lines using short tandem repeat profiling in June 2013. UV irradiation (10 mJ/cm 2 ) was performed without medium using a Stratalinker UV Crosslinker (Agilent Technologies, Santa-Clara, CA, USA) to cause DNA damage. The cells were then incubated in medium with 10% FBS for 24 h, and analyzed. The DNA-damaging agents cisplatin (CDDP) and 5-fluorouracil (5-FU) were purchased from Kyowa Hakko (Tokyo, Japan).
Ten pairs of frozen primary human GC tissues and corresponding normal mucosal tissues, obtained at least 5 cm from the tumor edge, were analyzed as the preliminary data set for expression and methylation status. Formalin-fixed, paraffin-embedded tissue samples were collected from 83 patients with primary GC who underwent a gastrectomy at the Kitasato University Hospital in accordance with the gastric cancer treatment guidelines in Japan (16) . Informed consent was obtained from all patients before sample collection.
All histopathological findings were examined in accordance with the 14 th edition of the Japanese Classification of Gastric Carcinoma (JCGC) (17) . Advanced gastric cancer is defined as cancer invading the muscularis propria or deeper, irrespective of the presence of lymph node metastases in JCGC. TNM classification was made accordance with the 7 th edition of the American Joint Committee on Cancer/International Union Against Cancer (AJCC/UICC) staging system. Detailed information on the 83 patients is summarized in Table 1 . This study was performed with approval of the Ethics Committee of Kitasato University.
Bisulfite Treatment of DNA and Sequencing Analysis
Tissue sections from the tumor and the corresponding normal mucosa were sharply dissected on hematoxylin-and-eosin-stained slides, and genomic DNA was subsequently extracted using a QIAamp DNA FFPE Kit (QIAGEN Sciences, Hilden, Germany).
Genomic DNA from cell lines and frozen tissues were extracted using a QIAamp DNA Mini Kit (QIAGEN). Bisulfite treatment was performed using an EpiTect Bisulfite Kit (QIAGEN) and was subsequently amplified via polymerase chain reaction (PCR). The PCR conditions and sequences of primers and probes used in this study are shown in Supplementary Table 1 . Primer sequences for Reprimo promoter region were designed to recognize DNA alterations caused by bisulfite treatment. The PCR products were purified and then inserted into a pCR Temecula, CA, USA) were used to construct the calibration curve for each plate. CpGenome TM universal methylated DNA and unmethylated DNA (Chemicon) were used as a methylation positive and a negative control, respectively. The methylation value was defined by the ratio of fluorescence intensity emitted from the amplified bisulfite DNA of the CpG islands of Reprimo gene divided by that of β-actin and multiplied by 100 (Q-MSP value). The optimal cut off value for Q-MSP was determined using a receiver operating characteristic (ROC) curve.
Quantitative-Reverse Transcriptase-Polymerase Chain Reaction (Q-RT-PCR)
Total RNA was isolated using TRIzol Reagent (Invitrogen) in accordance with the manufacturer's protocol and reverse-transcribed with a SuperScript III Reverse Transcriptase kit (Invitrogen). Quantitative-reverse transcriptase-PCR (Q-RT-PCR) was performed to quantify the expression level of Reprimo gene using the iCycler iQ TM RealTime PCR Detection System (Bio-Rad). Relative quantitative analysis normalized to β-actin was performed via the comparative cycle threshold method (19).
5-Aza-2'-Deoxycytidine (5-Aza-dC) Treatment
Cells (1×10 6 /T-75 flask) were treated with 5 µmol/L of the demethylating agent 5-aza-2'-deoxycytidine (5-Aza-dC; Sigma-Aldrich, St. Louis, MO, USA) dissolved in 50% acetic acid or were mock-treated with PBS including the same amount of acetic acid every 24 h for 5 days (20) .
Western Blot Analysis
Whole cell lysates were extracted in RIPA buffer (Pierce, Rockford, IL, USA) supplemented with 10 µL/mL Halt targeting Pool (siRNA-ctr) and Accell siRNA Delivery Media alone (siRNA-mock) were used as a control for non-sequence-specific effects and as a mock-treatment, respectively.
Anchorage-Independent Colony Formation Assay
Anchorage-independent cell growth was analyzed by plating 0.36% top agarose (Bacto 
Proliferation Assay and Invasion Assay
The effects of Reprimo expression on cell proliferation and viability (2×10 
Cell Cycle and Apoptosis Assays
Cell cycle and apoptosis assays were performed using the Guava PCA System (Guava Technologies, Inc., Hayward, CA, USA). In the cell cycle assay, after synchronization for 48 h in serum free medium, the cells were then cultured in complete medium. After 24 h, the cells (2×10 5 ) were then fixed in 75% ethanol, and stained with propidium iodide (Guava Cell Cycle Reagent). In the apoptosis assay, the harvested cells (1x10 5 ) were stained with Annexin V and 7-AAD (Guava Nexin Reagent) for discrimination of early and late apoptotic cells, respectively. Both experiments were performed in triplicate and analyzed using CytoSoft 2.1.5 software (Guava Technologies).
Mouse Xenograft Assay
Female BALB/cAJcl nude mice aged 5 weeks were purchased from CLEA Japan Inc. 
Statistical Analysis
Categorical variables were analyzed via Chi-square test or Mann-Whitney U-test, and continuous variables were analyzed via Student's t-test. For continuous variables, the data are expressed as mean ± standard deviation (SD). The disease-specific survival (DSS) was measured from the date of surgery to the date of death or the last follow-up. DSS was estimated via the Kaplan-Meier method, and values were compared using the log-rank test. 
Results

Cancer-Specific Reprimo Promoter Methylation in GC
The location of CpG islands in the 5'-flanking region of Reprimo genomic sequencing is shown in Figure 1A . The Reprimo promoter harbors CpG islands encompassing the transcription start site, and we previously reported that Reprimo harbored its promoter methylation in 75% (6/8) of GC cell lines, 80% (8/10) of primary human GC tissues, and 10% (1/10) of corresponding normal tissues in the preliminary data set of 10 matched pairs by bisulfite sequencing analysis (15) . Q-MSP can achieve a much more objective and specific assessment of a small amount of genomic DNA through PCR amplification using methylation-specific primers and fluorescent probes (22) . Q-MSP analysis was therefore performed using the same samples (15) We next examined the correlation of Reprimo methylation to clinical relevance using Q-MSP in 83 primary tumors and corresponding normal mucosa tissue specimens with human GC patients. The optimal cut-off value for distinguishing between tumor and normal tissues was calculated using a ROC analysis, and the best cut-off value of 0.42 showed a sensitivity of 69% and specificity of 82% ( Figure 2A ). Further, all cell lines or human samples with a Q-MSP value higher than 0.42 showed denser methylation on bisulfite sequencing with cloned PCR products (i.e. hypermethylation, Figure 1D ).
Reprimo promoter hypermethylation was found in 69% (57/83) of tumor tissues and 18% (15/83) of corresponding normal tissues, with both differences being statistically significant (P<0.0001, Figure 2B ). In addition, the Q-MSP values in tumor tissues were significantly higher than those in normal tissues, not only for different tumor stages, but also in individual patients (P<0.0001, Figure 2C ). These findings suggest that Reprimo promoter hypermethylation might be a frequent and early alteration that occurs specifically in the development of cancer.
Because some genes show age-related methylation alterations (23), the clinicopathological characteristics of Reprimo promoter hypermethylation were assessed. Although Reprimo promoter methylation was marginally associated with vascular invasion (P=0.058), no correlation was found between Reprimo promoter hypermethylation and clinicopathological factors, including aging and stage of tumor development (Table 1) .
Transcriptional Silencing by Reprimo Promoter Methylation
Reprimo was classified as a p53-mediated gene in embryonic fibroblast cells (9) . However, Reprimo promoter methylation is an alternative mechanism in the regulation of Reprimo expression in various tumor types (11) (12) (13) . Further, the regulation of Reprimo expression is independent of the p53 gene status in neuronal cells treated with copper (14) . Reprimo expression was recently reported to be repressed by a ligand-activated estrogen receptor via a mechanism involving histone deacetylase-7 and Fork head A1 in breast cancer (24) . Thus, Table 2 ). Reprimo promoter methylation was unrelated to p53 gene status ( Table 1 ).
Given that Reprimo expression was induced by X-ray irradiation as the DNA damage in embryonic fibroblast cells with p53 wild type (9), we examined whether or not 
showed significantly decreased cell size and colony number ( Figure 4B ), but no decrease in matrigel invasive ability (Supplementary Figure 2A) Figure   5A and 5B). Tumor weight was also significantly decreased in mice injected with AZ-r10 or AZ-r16 cells ( Figure 5C ). As Reprimo promoter methylation was marginally associated with vascular invasion in 83 patients with GC (Table 1) Figure 3) .
Potential Utility of Reprimo Methylation as a Predictive Marker
The most promising candidate epigenetic marker reported thus far for the prediction of chemoresistance. Therefore, the methylation of MGMT is a predictor of a favorable response to temozolomide in gliomas (28) . In the present study, we found that Reprimo could enhance 5-FU or CDDP-mediated apoptosis in GC. The combination of CDDP and fluoropyrimidine class, including 5-FU, capecitabine, or S-1, was the most standard regimen of chemotherapy against GC (29, 30) . We therefore analyzed 83 human GC samples to evaluate whether or not assessment of Reprimo methylation could be a predictive marker for chemotherapy combined with CDDP and fluoropyrimidine class. Of the 49 patients who received a combination regimen for metastatic or recurrent GC, 41 had measurable lesions. The tumor response was assessed according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 (31) . Reprimo promoter hypermethylation, previously defined as a value greater than 0.42 on Q-MSP, was inversely associated with the response rate (P=0.028, Table1), and showed a trend towards a worsening prognosis, compared with absence of Reprimo promoter methylation ( Figure 5E ).
We next examined whether or not the assessment of Reprimo hypermethylation could be used to predict patient prognosis and thereby serve as a marker for tumor aggressiveness in 68 patients with advanced GC. Reprimo promoter hypermethylation had a significantly poor outcome (P=0.031, Figure 5F ). In multivariate analysis, Reprimo promoter hypermethylation was independently associated with a poor prognosis, with a hazard ratio of 2.148 (P= 0.026; Supplementary Table 3) . We previously reported that Reprimo promoter methylation was one of the most frequent cancer-specific alterations, using bisulfite sequencing analysis in primary GC tissues (15) .
Of note, many of the methylation alterations are tissue-specific or associated with the field of cancerization, but are not cancer-specific (32) . As such, we examined the epigenetic inactivation, biological function, and clinical relevance in GC in the present study.
In GC cell lines without Reprimo promoter methylation, we observed an unexpectedly faint or weak Reprimo expression under normal conditions but a robust expression under DNA-damaging conditions. In GC cell lines with Reprimo promoter methylation, however, we observed faint expression even under DNA-damaging conditions, with expression being restored only in combination with the demethylating agent. In 83 human GC samples, Reprimo promoter methylation was a cancer-specific alteration that frequently occurred at an early stage in the development of cancer and was not related to p53 status. Thus, Reprimo promoter methylation may be the predominant mechanism for loss of DNA damage-inducible Reprimo expression, regardless of p53 status.
Although promoter methylation alterations are common events in human cancers, most are merely passengers that have no effect per se on the process of carcinogenesis. In contrast, driver methylation mainly inactivates tumor-suppressive activity, leading to the processes of tumor initiation, progression or metastasis. Thus, the identification of driver methylation will be of key importance for cancer etiology, development of biomarkers, and therapeutic targets (33) . Enforced Reprimo expression robustly inhibited tumor cell growth, including cell proliferation and anchorage-independent colony formation. In addition, the cell-cycle distribution showed a significantly increased sub-G1 population, but not G2 Three major clinical oncology areas can potentially benefit from DNA methylationbased biomarkers: cancer detection, tumor prognosis and prediction of treatment responses (34) . The cancer-specific Reprimo promoter methylation that occurs at an early stage in disease development can serve as a potential biomarker for early detection in GC. Indeed, Reprimo promoter methylation was frequently detected in plasma from patients with GC (11) . Further, Reprimo promoter methylation is significantly lower in chemoradiotherapyresponders than in non-responders in esophageal cancer (35) , and is predictive of a poor prognosis in pancreatic ductal carcinoma (36) . Reprimo promoter methylation was inversely associated with response to the treatment combined with CDDP and the fluoropyrimidine class as a standard chemotherapy. In addition, Reprimo expression enhanced CDDP or 5-FU-mediated apoptosis in vitro, and anticancer effect of treatment combined with CDDP and 5-FU in vivo. We were unable to assess any association between Reprimo protein level and response to chemotherapy due to lack of a commercially available antibody. However, Reprimo expression is induced by DNA damage, and as such, potential functionality of Reprimo as tumor-suppressive activity may not be reflected by expression level of mRNA or protein at diagnosis. At present, the assessment of Reprimo promoter methylation may be useful in predicting response to chemotherapy with CDDP and the fluoropyrimidine class. Further, Reprimo promoter methylation in advanced GC patients was an independent prognostic factor reflecting an aggressive tumor phenotype, indicating that Reprimo promoter methylation is one of the most critical alterations in cancer progression and is also a potential marker for tumor aggressiveness.
In the last decade, a number of landmark trials have demonstrated efficacy of multimodality therapy in resectable GC, such as perioperative chemotherapy (37), adjuvant chemoradiotherapy (38), adjuvant chemotherapy (39, 40) , and neoadjuvant chemoradiotherapy (41) . However, the therapeutic strategies by which clinicians distinguish between the various treatment options remain a contentious issue. One point of clinical importance is that, although preoperative therapy has the potential to improve the therapeutic outcome for responders (42) , it runs the risk of shifting the status of nonresponders from potentially resectable to unresectable, despite that radical resection is the only curative treatment modality, requiring the predictive marker for treatment response. 
In conclusion, Reprimo expression is normally induced in response to DNA damage, robustly inhibiting tumorigenesis through enhancing apoptosis as a novel tumor-suppressor in GC. Methylation of the Reprimo promoter is a frequent and cancer-specific event that abrogates its expression and functions in p53 independent manner. In addition, clinical assessment of Reprimo promoter methylation may serve not only as a predictive marker for chemotherapy consisting of CDDP and the fluoropyrimidine class, but also as a marker for tumor aggressiveness. Further research will be necessary to validate the clinical potential of Reprimo promoter methylation as a biomarker in GC. 
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